Ovidrel Solution for Injection 250 mcg

INJECTION, SOLUTION

**Posology** Treatment with Ovidrel® should be performed under the supervision of a physician experienced in the treatment of fertility problems. The maximum dose is 250 micrograms. The following dosing regimen should be used: - Women undergoing superovulation prior to assisted reproductive technologies (ART) such as in vitro fertilisation (IVF): One pre-filled pen of Ovidrel® (250 micrograms) is administered 24 to 48 hours after the last administration of a follicle stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e. when optimal stimulation of follicular growth is achieved. - Anovulatory or oligo-ovulatory women: One pre-filled pen of Ovidrel® (250 micrograms) is administered 24 to 48 hours after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of, and the day after, Ovidrel® injection. **Method of administration** For subcutaneous use. Self-administration of Ovidrel® should only be performed by patients who are adequately trained and have access to expert advice. Ovidrel® is for single use only. For instructions on the administration with the prefilled pen, see ‘Instructions for Use’ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.